Abstracts A177 (QALYs) gained. Model probabilities were obtained from a systematic review involving international published trials. Comparators used in the assessment were lorazepam (6 mg/day); alprazolam (1.5 mg/day); venlafaxine (75 mg/day) and pregabalin (150-600 mg/day). Resource use and costs were obtained by a panel of Mexican experts through the Delphi technique and offi cial institutional databases. Costs include outpatient and inpatient services, drug, procedures, etc. The model was validated according to international guidelines. One-way and probabilistic sensitivity analyses were performed and acceptability curves were constructed. RESULTS: Pregabalin had the highest percentage of patients with over 50% reduction on the HAM-A scale (64.7%); followed by venlafaxine (54.1%), lorazepam (40.8%) and alprazolam (38.2%). Regarding QALYs the highest results corresponded to pregabalin (0.1838QALYs); followed by venlafaxine (0.1787QALYs), alprazolam (0.1776QALYs) and lorazepam (0.1753QALYs). OBJECTIVES: The present cost-effectiveness analyses compare escitalopram versus duloxetine and generic venlafaxine in second-line MDD treatment, to inform decisionmaking on effi cient second-line therapy choice. METHODS: A decision model was based on second-line MDD treatment patterns (6-month timeframe). Effectiveness outcomes were sustained remission (the Montgomery-Asberg Depression Rating Scale (MADRS) 12 at 2 months, sustained till the end of, month 6) and quality-adjusted life years (QALY). Total cost included health care and absenteeism costs. Clinical inputs were derived from pooled analyses of randomized clinical trials on the secondline patients subgroup. Health care resource utilization was assessed from a Swedish observational cohort (HEADIS) and UK General Practice Research Database (GPRD). Utility estimates were based on HEADIS and US panel survey. Unit costs were from standard sources. Due to unavailability of generic venlafaxine unit cost, it was assumed equal to that of escitalopram in Scenario 1, and 5% of the brand venlafaxine cost in Scenario 2. RESULTS: Over 6 months, a sustained remission rate was 56% for escitalopram and 38% for SNRIs (18% difference, 95% Credibility Interval (CrI) 0.8% to 32.9%)). The incremental QALY for escitalopram versus both comparators was 0.024 (95% CrI 0.006 to 0.042). Per patient savings with escitalopram versus venlafaxine were 670 USD (95% CrI 6689 to 4481) in Scenario 1 and US$565 USD (95% CrI 6588 to 4583) in Scenario 2. Versus duloxetine, savings were USD615, 95% CrI (6670 to 4554). With willingness to pay 42,500 USD (equivalent to 350,000 SEK) per QALY, escitalopram was cost effective versus venlafaxine with probabilities 86% and 61.7% in Scenarios 1 and 2, respectively, and with 85.4% probability versus duloxetine. CONCLUSIONS: Escitalopram is cost-effective versus venlafaxine and duloxetine in second-line treatment of MDD in Sweden. The higher sustained remission rate and QALYs are associated with cost savings and support use of escitalopram following failure of fi rst-line treatment.
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Gibson TB 1 , Jing Y 2 , Carls GS 1 , Kim E 2 , Bagalman JE 3 , Burton WN 4 , Tran QV 5 , Pikalov A 5 , Goetzel RZ 6 1 Thomson Reuters, Ann Arbor, MI, USA, 2 Bristol-Myers Squibb, Plainsboro, NJ, USA, 3 Thomson Reuters, WASHINGTON, DC, USA, 4 University of Illinois, Chicago, IL, USA, 5 Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 6 Emory University/Thomson Reuters, Washington, DC, USA OBJECTIVES: Many patients on antidepressants are not responsive to fi rst-line therapy ('treatment-resistant' depression [TRD] ) and can undergo switches and optimizations to discover a benefi cial therapeutic regimen. While patients with more complex forms of TRD have higher costs than non-TRD patients, little is known about the cost effects for patients along a gradient of TRD classifi cations (from moderate to complex). METHODS: Patients aged 18-64 years in employer-sponsored plans with at least three years of continuous medical and prescription coverage and at least one antidepressant prescription were found in the 2000 -2006 ). An MGH TRD scale value (range from 0 to 16.5) was calculated for each patient and a value exceeding 3.5 indicated TRD. Twelve-month direct medical and prescription drug expenditures for patients with TRD (n 22,593) were compared to expenditures among an equal number of propensity-score matched patients with non-TRD depression. Propensity scores were estimated via demographic characteristics and case-mix. Generalized linear models (gamma family and log link) controlled for demographic and case-mix factors. RESULTS: Average 12-month direct medical care and prescription drug expenditures were almost 40% higher for TRD ($9470) compared to matched non-TRD patients ($6813) (p 0.01). A one-unit increase in TRD score was associated with a $772 increase in annual costs (p 0.01). Compared with a matched group of non-TRD patients, annual costs for patients were higher in each MGH score catergory: 3.5-4, 23.6%; 4.5-5, 32.9%; 5.5-6, 44.6%; 6.5 , 61.1% (all p 0.01). CONCLUSIONS: TRD is a costly disorder and merits consideration as interventions are developed to manage the burden of disease and improve productivity. Even patients with less complex forms of TRD have costs far in excess of those without TRD. Dichotomous defi nitions of TRD may not be adequate; a gradient from moderate to complex TRD may be more useful for providers and insurers. Istanbul, Istanbul, Turkey OBJECTIVES: Schizophrenia, infl uencing approximately 1% of the population, is a chronic psychiatric disease with a substantial health and economical burden for patients, care givers, and society. Despite this, however, its economic burden is often overlooked and/or not widely known in many countries. This study aims at estimation of cost of schizophrenia treatment in an inpatient facility in Turkey. METHODS: The study has been conducted in Manisa Mental Diseases Training and Research Hospital, one of the largest of its type in Turkey. Electronic hospital records of 4177 schizophrenia patients between June 2006 and June 2007 were retrospectively analyzed to calculate the total schizophrenia treatment cost per hospitalization where only direct costs were included. Cost items included in the analyses were antipsychotic and concomitant medication costs, adverse event treatment costs, bed costs, and laboratory/ radiological examination costs. Average length of stay per hospitalization was calculated. Results were presented as average daily and total costs of treatment per hospitalization. Composition of the total cost was also presented. RESULTS: Mean length of stay per hospitalization was 30.80 17.18 days. Mean daily total cost was TL 52.68 41.30. Mean total treatment cost per hospitalization was TL 1431.86 798.74. Costs for antipsychotic drugs, concomitant medications, adverse event treatment, bed, and laboratory/radiological examinations were 31%, 2%, 1%, 40%, and 26% respectively. CONCLUSIONS: The share of drug costs may be relatively higher than they are in other countries due to relatively lower costs for non-drug cost items in Turkey. This may also stem from the case-mix in this hospital that may care more for severe cases needing tertiary care. This study may stimulate further studies which would help to generate a fuller picture of economic burden of schizophrenia in Turkey.
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